Clinical trials: Open Angle Glaucoma -Ocular Hypertension
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Glaucoma, Glaucoma Patient
Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma Management
Glaucoma is one of the leading causes of irreversible vision loss worldwide. Elevated intraocular pressure (IOP) is the most important risk factor for the development and progression of the disease.
- Conditions
- Glaucoma, Glaucoma Patient, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Glaucoma Following Surgery
- Trial name
- NCT07780916
- Testing
- Ab-interno trabeculotomy
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Wuerzburg University Hospital
Primary Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension…
- Trial name
- NCT04620135
- Testing
- Netarsudil ophthalmic solution 0.02%, Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
- Where
- Japan
- Volunteers
- 245 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Mirtogenol and Bimatoprost on IOP in Hispanics With Open-Angle Glaucoma
A prospective, parallel-group, double-blind, randomized placebo-controlled clinical study will be conducted with an estimated 72 participants.
- Trial name
- NCT04380025
- Testing
- Experimental: Oral Mirtogenol
- Where
- Puerto Rico
- Volunteers
- 72 people
- Sponsor
- University of Puerto Rico
Open Angle Glaucoma
Clinical Evaluation of Visco-Assisted CyPass® Micro-Stent Implantation in Patients With Open Angle Glaucoma
The purpose of this study is to assess the safety and effectiveness of the use of visco-assisted CyPass® Micro-Stent implantation for the lowering of intraocular pressure (IOP) in subjects who have open angle glaucoma (OAG).
- Trial name
- ViscoPass (NCT02448875)
- Testing
- CyPass Micro-Stent, Viscoelastic
- Where
- 6 sites in Germany, Panama and 2 more
- Volunteers
- 192 people
- Sponsor
- Transcend Medical, Inc.
Open-angle Glaucoma, Ocular Hypertension
IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with…
- Trial name
- NCT00527501
- Testing
- Travoprost/brinzolamide
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Cosopt Versus Xalacom
To compare the intraocular pressure efficacy and safety of the DTFC given twice daily versus the LTFC given once every morning following a run-in period with timolol maleate given twice daily.
- Trial name
- NCT00273481
- Testing
- dorzolamide 2%/timolol maleate 0.5% fixed combination, latanoprost 0.005%/timolol maleate 0.5% fixed combination, timolol maleate 0.5%
- Where
- 2 sites in Canada, Slovenia
- Volunteers
- 33 people
- Sponsor
- Pharmaceutical Research Network
Primary Congenital Glaucoma
Evaluation of Primary Congenital Glaucoma at Asyut University Hospital
Evaluation of the management of primary congenital glaucoma regarding the results of surgical intervention at Asyut University Hospital
- Trial name
- NCT05205122
- Testing
- Combined trabeculotomy-trabeculectomy with mitomycin C
- Volunteers
- 30 people
- Sponsor
- Omar Abdelkarem Hasan
Open-angle Glaucoma, Ocular Hypertension
Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Eligible patients will be randomized in a 1.1 ratio to receive Travoprost 0.004%/timolol 0.5% once daily or Latanoprost 0.005%/Timolol 0.5% once a day for 8 Weeks.
- Trial name
- NCT00872651
- Testing
- Travoprost 0.004%/Timolol 0.5%, Latanoprost 0.005% / Timolol 0.5%
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
Evaluate the effectiveness of dorzolamide-timolol (Cosopt®) as first line therapy in reducing intraocular pressure in patients with untreated Open angle glaucoma (OAG) or Ocular hypertension (OH).
- Trial name
- NCT00546286
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: dorzolamide HCl/timolol maleate + prostaglandin
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma, Open Angle
Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure
Glaucoma is one of the leading causes of blindness worldwide and trabeculectomy is the most commonly performed operation to slow-down the disease progression.
- Trial name
- BCATS (NCT02114073)
- Testing
- Cyclosporine, Betamethasone
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Mashhad University of Medical Sciences
Primary Open Angle Glaucoma (POAG)
iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
- Trial name
- NCT03478293
- Testing
- iStent inject surgery
- Where
- Brazil
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
The Effects of DSLT and SLT on the Corneal Endothelium: A GLAUrious Trial Sub-Study
The objective of this study is to compare the long-term (6 months) effects of Direct Selective Laser Trabeculoplasty (DSLT) treatment and SLT (Selective Laser Trabeculoplasty) treatment on corneal endothelial cell counts and…
- Trial name
- NCT04758598
- Testing
- Direct Selective Laser Trabeculoplasty (DSLT), Selective Laser Trabeculoplasty (SLT)
- Where
- Georgia
- Volunteers
- 20 people
- Sponsor
- BelkinVision
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM…
- Trial name
- NCT04405245
- Testing
- Latanoprost ophthalmic solution, AKB-9778 4%
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- LUNAR (NCT01749930)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Open Angle Glaucoma (OAG)
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
- Trial name
- NCT06933836
- Testing
- DSLT enables newly diagnosed patients to remain well controlled and off medications
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Barnet Dulaney Perkins Eye Centers
Glaucoma, Open-Angle, Ocular Hypertension
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
- Trial name
- NCT02247804
- Testing
- Bimatoprost SR, Active Comparator: Timolol 0.5%
- Where
- 106 sites in United States, Australia and 12 more
- Volunteers
- 594 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.